Free press releases distribution network?

Agency / Source: IPSEN Group

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib - Ipsen today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib - Europa.eu / IPSEN.com
EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

 

PRTODAY - Newswire & PRZOOM/ - Paris, Ile-de-France, France, 11/15/2018 - Ipsen today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib - Europa.eu / IPSEN.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This approval allows for the marketing of Cabometyx® (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland.

“Today’s EC approval for the use of Cabometyx® provides a much needed new option for HCC patients. Until now, physicians in Europe had only one approved therapy for the 2nd line treatment of this aggressive and difficult-to-treat cancer.[i], [ii] We are proud to offer Cabometyx® as an innovative treatment that has been shown to extend survival in previously treated patients with HCC”, said Harout Semerjian, Chief Commercial Officer, Ipsen,“This new indication reinforces Ipsen’s commitment to improve patients’ lives through the expansion of the clinical benefit of Cabometyx® in the treatment of solid tumors.”

Philippe Merle, M.D., Ph.D., Hepatology and Gastroenterology specialist at La Croix-Rousse Hospital, Lyon, stated: “Patients with HCC in Europe can now benefit from a treatment that has, through the CELESTIAL trial, proven effective in prolonging life and delaying disease progression. This is a very encouraging development for liver cancer patients, and provides physicians with a new therapeutic option for this complex disease.”

The EC approval is based on the results of the global placebo-controlled CELESTIAL phase 3 pivotal trial which met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and clinically meaningful improvement in OS compared with placebo in patients with advanced HCC who have been previously treated with sorafenib.[iii] In July 2018, CELESTIAL phase 3 pivotal trial results were published in the New England Journal of Medicine.3

The EC has also approved Cabometyx® for the treatment of advanced renal cell carcinoma (aRCC) both in treatment-naïve adults with intermediate or poor risk (May 2018) and in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy (September 2016).

References:

[i] Stivarga (regorafenib) EU Summary Of Product Characteristics
[ii] ESMO HCC Clinical Guidelines, Ann Oncol 2018 ; 29 (Supplement 4): iv238 iv255, 2018
[iii] Abou-Alfa GK et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: IPSEN Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+] [Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
Ipsen | European Commission (EC)
Contact: Ian Weatherhead - IPSEN.com 
+44(0)17 5362 7733 ian.weatherhead[.]ipsen.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with SorafenibAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From IPSEN Group / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib
Ipsen and 3BP Announce First Patient Dosed in Phase I/II study for First-in-Class Radionuclide (IPN01087)
Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan
Market Entrants Offering Digitized Mass Spectrometry Solutions Gain a Competitive Edge over Traditional Vendors Finds Frost & Sullivan
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
Medtech & Pharma Platform Annual Event Celebrates its 5th Anniversary in Basel
Ipsen to Present New Data from its Oncology Portfolio At The 2018 European Society for Medical Oncology (ESMO) Congress
Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10
SCHOTT Teams Up with Smart Skin Technologies
STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  Limelon Advertising, Co.

Visit  TTP HARD Drills Ltd

Visit  JobsWare.com





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)